Alnylam Pharmaceuticals, Inc. (LON:0HD2)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 28.87B +17.2% |
| Revenue (ttm) | 3.25B +82.6% |
| Net Income | 407.42M |
| EPS | 2.99 |
| Shares Out | n/a |
| PE Ratio | 70.86 |
| Forward PE | 27.45 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 65 |
| Average Volume | 479 |
| Open | 292.50 |
| Previous Close | 293.92 |
| Day's Range | 289.27 - 298.49 |
| 52-Week Range | 254.14 - 500.21 |
| Beta | 0.30 |
| RSI | 41.14 |
| Earnings Date | Apr 30, 2026 |
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amylo... [Read more]
News
Alnylam Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
The company is leveraging its RNAi platform to drive profitable growth, with strong AMVUTTRA sales and ambitious 2026 guidance. Pipeline investments focus on next-generation TTR therapies and new indications, while robust cash reserves support both internal and external innovation.
Alnylam announces new analyses from HELIOS-B study of vutrisiran
Alnylam (ALNY) announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, adding to the gro...
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in pa...
MBX Biosciences appoints Mark Soued as chief commercial officer.
MBX Biosciences (MBX) announced the appointment of Mark Soued as chief commercial officer. Most recently, Soued served as senior VP, head of U.S. at Alnylam Pharmaceuticals (ALNY). Published first on…
Alnylam to Webcast Presentations at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following ...
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients wit...
Alnylam price target raised to $370 from $360 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Alnylam (ALNY) to $370 from $360 and keeps an Equal Weight rating on the shares.
Alnylam price target lowered to $447 from $448 at Bernstein
Bernstein lowered the firm’s price target on Alnylam (ALNY) to $447 from $448 and keeps an Outperform rating on the shares. The firm notes Amvuttra beat consensus by 5%. Shares…
Alnylam reports Q1 EPS $1.99, consensus $1.47
Reports Q1 revenue $1.167B, consensus $1.12B. “2026 is off to a strong start for Alnylam (ALNY) with the end of the first quarter marking one year since the U.S. launch…
Alnylam Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw record net product revenues exceeding $1 billion, driven by robust TTR franchise growth and strong rare disease performance. The company reiterated full-year guidance, advanced its pipeline, and maintained high gross margins despite royalty headwinds.
Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended Ma...
Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter endi...
Alnylam price target lowered to $505 from $515 at Truist
Truist lowered the firm’s price target on Alnylam (ALNY) to $505 from $515 and keeps a Buy rating on the shares as part of a broader research note previewing Q1…
BioCryst appoints Sandeep Menon as chief research and development officer
BioCryst (BCRX) announced the appointment of Sandeep Menon as chief research and development officer. Menon joins BioCryst from Alnylam (ALNY), where he served as chief development officer, overseeing...
Alnylam presents new data on vutrisiran in ATTR-CM at ACC.26
Alnylam (ALNY) Pharmaceuticals announced new clinical and real-world data from its cardiovascular portfolio presented at the American College of Cardiology’s Annual Scientific Session and Expo, reinfo...
Alnylam presents new data on potential of zilebesiran for hypertension
Alnylam (ALNY) presented pooled Phase 2 safety data for zilebesiran, an investigational RNAi therapeutic being evaluated for cardiovascular risk reduction in patients with hypertension, with the poten...
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new clinical and real-world data from its cardiovascular (CV) po...
Alnylam Pharmaceuticals Transcript: Status update
AMVUTTRA has rapidly gained market share in ATTR cardiomyopathy, driving strong revenue growth and broad physician adoption. Clinical data support its differentiated profile, while strategic investments in diagnosis, access, and innovation position it for sustained leadership and expansion globally.
Viz.ai Partners with Alnylam Pharmaceuticals to Advance Earlier Identification and Care Coordination in Cardiac Amyloidosis
SAN FRANCISCO--(BUSINESS WIRE)-- #ai--Viz.ai, the leader in AI-powered disease detection and care coordination, today announced a partnership with Alnylam Pharmaceuticals, the leading RNAi therapeutic...
Alnylam announces set of efforts to improve care for patients with ATTR-CM
Alnylam (ALNY) Pharmaceuticals announced a set of strategic efforts designed to accelerate earlier recognition and improve care coordination for patients with the cardiomyopathy of wild-type or heredi...
Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier recogn...
Alnylam downgraded to Hold from Buy at Jefferies
Jefferies downgraded Alnylam (ALNY) to Hold from Buy with a price target of $330, down from $522, after assuming coverage of the name. The firm is “impressed” with the company’s…
How Alnylam Stock Weathers Market Shocks
Investing in equities involves accepting volatility as the cost of long-term compounding. In 15 significant systemic shocks during which Alnylam Pharmaceuticals (ALNY) was traded, the stock experience...
Alnylam to Webcast TTR Investor Webinar
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the In...